FDA Panel Opposes Lowering BMI Criteria For Obesity Clinical Trials
This article was originally published in The Tan Sheet
Executive Summary
A majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee members recommended against lowering the body mass index for clinical trials involving weight-loss drugs
You may also be interested in...
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy